17 June 2019 Comment
Promising results for Astellas/Pfizer’s Xtandi and J&J’s Erleada were revealed at the annual American Society of Clinical Oncology (ASCO 2019) meeting in Chicago in early June.
9 May 2019 Comment
Only about 20% of patients who have the castration-resistant disease have nmCRPC, with the rest being metastatic.
5 April 2019 News
Gilead has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for antiviral Descovy (emtricitabine and tenofovir alafenamide) for pre-exposure prophylaxis (PrEP) to reduce...
2 April 2019 Comment
Scientists have detailed a mechanism by which Engrailed-2 (EN2) may provide a mode of communication between prostate cancer cells and the surrounding stroma.
28 March 2019 News
Clarus Therapeutics has announced that the US Food and Drug Administration (FDA) has approved its oral testosterone undecanoate (TU) Jatenzo for testosterone replacement therapy.
20 March 2019 Comment
On the back of positive results from their Phase III trial of darolutamide in men with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC), Bayer and Orion have filed for approval to...
14 February 2019 Analysis
Erectile dysfunction affects around 50% of men between 40 and 70 years old. Futura Medical is currently developing a topical gel product, named MED2005, as a new therapeutic approach for...